The Effect of Penehyclidine Hydrochloride on Preventing Postoperative Nausea and Vomiting in Patients Undergoing Thyroid Surgery Under General Anesthesia: A Randomized Double-Blind Controlled Study

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2500107170

Enrollment

Unknown

Registered

2025-08-05

Start date

2025-08-11

Completion date

Unknown

Last updated

2025-08-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Postoperative nausea and vomiting

Interventions

Penehyclidine group:Intravenous penehyclidine

droperidol group:Intravenous droperidol

Eligibility

Sex/Gender

Female

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. Aged 18–65 years, ASA physical status I–II; 2. Body mass index (BMI) 18–28 kg/m^2; 3. Scheduled to undergo thyroid surgery under general anesthesia.

Exclusion criteria

Exclusion criteria: 1. History of glaucoma or intraocular pressure >21 mmHg; 2. Hypersensitivity to anticholinergic drugs, and/or known allergy to penehyclidine hydrochloride or any of its excipients; 3. Pre-existing acute/chronic nausea/vomiting or gastrointestinal motility disorders; 4. Mental or cognitive impairment; 5. Hepatic or renal dysfunction.

Design outcomes

Primary

Measure	Time frame
Incidence of PONV within 24 hours after surgery;	—

Secondary

Measure	Time frame
Incidence of PONV 2 hours after surgery;Severity of PONV at 2 hours and 24 hours postoperatively;Time of patients falling asleep;Patient recovery time;Perioperative adverse reactions;Perioperative hemodynamic changes;	—

Countries

China

Contacts

Public ContactFanceng Ji

Weifang People's Hospital

jifanceng@163.com+86 135 6369 8838

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026